incidence and prevalence of anemia in cancer patients
Cancer anemia is present in 40% of neoplastic patients. Anemia is mild in 30%, moderate in 9% and severe in 1% of patients. Overall incidence of anemia during chemo-or radiotherapy is 54% (mild 39%, moderate 14%, severe 1%). The incidence is highest in lung (71%) and gynaecological cancers (65%) and increases with the number of chemotherapy cycles. High grade of anemia has a negative impact on the performance status and is a major though not the only cause of fatigue, one of the most prevalent and important symptoms of cancer (Table 1) .
indication for the use of erythropoietins in anaemic patients with solid cancers
The aim of treating anemia in cancer patients receiving chemotherapy is to reduce the need for red blood cell transfusions. Erythropoietins have not been shown to improve the outcomes of chemotherapy treatment (i.e. better tumor shrinkage, delayed tumor growth or longer survival) [I, A]. Furthermore, data on their effect on health-related quality of life outcomes should be interpreted with caution. Considering the risk of using erythropoietins when hemoglobin levels are >12 g/dl (see cancer therapy outcome and safety and tolerability sections) erythropoietins should only be used in cancer patients with chemotherapy-associated anemia and a Hb concentration of 9-11g/dl [I, A].
myelodysplastic syndromes
Erythropoietin + best supportive care 6 granulocyte colonystimulating factors (G-CSF) increases response rates over best supportive care alone [II, B] . Response rates for unselected patients are low (10% for erythropoietin and 35% for erythropoietin + G-CSF). Patients with low-risk myelodysplasia (i.e. refractory anemia, refractory anemia with ringed sideroblasts) and erythropoietin levels <500 U/l may obtain the greatest benefit. Optimal duration of treatment is uncertain, the gain in quality of life is controversial and the costs are very high.
cancer therapy outcome
Several randomized trials, some published in peer-reviewed journals and some available in ODAC briefing documents posted on the US Food and Drug Administration web site have demonstrated decreased survival times or poorer locoregional control or progression-free survival in cancer patients receiving erythropoietins [I, A]. All but one of these studies, carried out in cancer patients treated or not with chemotherapy or radiotherapy, had a target Hb level >12 g/dl. Therefore, attempts to increase Hb above 12 g/dl may be harmful and should be restricted to clinical trials. Furthermore, erythopoietins should not be recommended to treat anemia of cancer, among patients with either solid or non-myeloid hematological malignancies who are not receiving concurrent chemotherapy or radiotherapy [I, A]. Reasons for these results 
